Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [1] Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy
    Hakozaki, Taiki
    Hosomi, Yukio
    Shimizu, Akihiro
    Kitadai, Rui
    Mirokuji, Kie
    Okuma, Yusuke
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (10) : 2659 - 2668
  • [2] Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
    Hakozaki, Taiki
    Richard, Corentin
    Okuma, Yusuke
    Derosa, Lisa
    Elkrief, Arielle
    Zitvogel, Laurence
    Routy, Bertrand
    Hosomi, Yukio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
    Ali, Wael Abdullah Sultan
    Hui, Pan
    Ma, Yuxiang
    Wu, Yuehan
    Zhang, Yang
    Chen, Yukun
    Hong, Shaodong
    Yang, Yunpeng
    Huang, Yan
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (22)
  • [4] Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
    Valecha, Gautam Kishore
    Vennepureddy, Adarsh
    Ibrahim, Uroosa
    Safa, Firas
    Samra, Bachar
    Atallah, Jean Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (01) : 47 - 59
  • [5] Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study
    Morikawa, Noboru
    Naito, Tateaki
    Morita, Meiko
    Sekikawa, Motoki
    Doshita, Kosei
    Yabe, Michitoshi
    Kodama, Hiroaki
    Miura, Keita
    Iida, Yuko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Ko, Ryo
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Takahashi, Toshiaki
    JOURNAL OF GERIATRIC ONCOLOGY, 2024, 15 (07)
  • [6] Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
    Nishioka, Naoya
    Uchino, Junji
    Hirai, Soichi
    Katayama, Yuki
    Yoshimura, Akihiro
    Okura, Naoko
    Tanimura, Keiko
    Harita, Sachi
    Imabayashi, Tatsuya
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Yamada, Tadaaki
    Takayama, Koichi
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (04)
  • [7] PD-L1+CD4+T cells and soluble PD-L1 as prognostic factors to anti-PD-1 immunotherapy in advanced non small cell lung cancer patients.
    Vetsika, EleniKyriaki
    Aggouraki, Despoina
    Lyristi, Zacharoula
    Koukos, Aristeidis
    Kourougkiaouri, Despoina
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
    Qu, Jingjing
    Mei, Quanhui
    Liu, Li
    Cheng, Tianli
    Wang, Peng
    Chen, Lijun
    Zhou, Jianying
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [9] Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
    Califano, Raffaele
    Lal, Rohit
    Lewanski, Conrad
    Nicolson, Marianne C.
    Ottensmeier, Christian H.
    Popat, Sanjay
    Hodgson, Matthew
    Postmus, Pieter E.
    FUTURE ONCOLOGY, 2018, 14 (23) : 2415 - 2431
  • [10] Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang, Yaxiong
    Zhou, Huaqiang
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345